A phase II study of oral vinorelbine in combination with cisplatin conducted in Taiwan in patients with unresectable localized or metastatic non-small cell lung carcinoma.

[1]  A. Rossi,et al.  Chemotherapy of advanced non-small cell lung cancer in elderly patients. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  V. Gebbia,et al.  Oral versus intravenous vinorelbine: clinical safety profile , 2005, Expert opinion on drug safety.

[3]  D. Galetta,et al.  O-090 Weekly vinorelbine plus cisplatin versus day 1+8 vinorelbine withcisplatin in advanced non small cell lung cancer: End results of a phase III trial , 2005 .

[4]  V. Georgoulias,et al.  Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  S. Barni,et al.  Phase II trial of oral vinorelbine in combination with cisplatin followed by consolidation therapy with oral vinorelbine in advanced NSCLC. , 2005, Lung cancer.

[6]  R. Stahel,et al.  Oral vinorelbine given as monotherapy to advanced, elderly NSCLC patients: a multicentre phase II trial. , 2004, European journal of cancer.

[7]  N. Saijo,et al.  The Four-Arm Cooperative Study (FACS) for advanced non-small-cell lung cancer (NSCLC). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  R. Ramlau,et al.  Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  P. Berger,et al.  Christianity and Democracy: The Global Picture , 2004 .

[10]  Thomas K. Schulz,et al.  Oral vinorelbine for the treatment of metastatic non-small cell lung cancer in elderly patients: a phase II trial of efficacy and toxicity. , 2004, Lung cancer.

[11]  Thomas J. Smith,et al.  American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  R. Ramlau,et al.  Oral vinorelbine in combination with cisplatin: a novel active regimen in advanced non-small-cell lung cancer. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  Yuh-Min Chen,et al.  P-544 Final results of a phase I study with navelbine (NVB) oral in combination with cisplatin (C), evaluating two different schedules in advanced non-small cell lung cancer (NSCLC) patients , 2003 .

[14]  E. Lemarié,et al.  Oral vinorelbine: feasibility and safety profile. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  E. Lemarié,et al.  A multicenter randomized phase II study of oral vs. intravenous vinorelbine in advanced non-small-cell lung cancer patients. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  F. Bray,et al.  Cancer burden in the year 2000. The global picture. , 2001, European journal of cancer.

[17]  J. Whang‐Peng,et al.  A phase II trial of vinorelbine and cisplatin in previously untreated inoperable non--small-cell lung cancer. , 2000, American journal of clinical oncology.

[18]  J. Crowley,et al.  Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  T R Fleming,et al.  One-sample multiple testing procedure for phase II clinical trials. , 1982, Biometrics.

[20]  P Langenberg,et al.  On the Colton model for clinical trials with delayed observations -- normally-distributed responses. , 1981, Biometrics.

[21]  A. Jemal,et al.  Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.

[22]  D. Caillaud,et al.  Sequential two-line strategy for stage IV non-small-cell lung cancer: docetaxel-cisplatin versus vinorelbine-cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: final results of a randomised phase II study. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  F. Sperandi,et al.  Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer. , 2005, European journal of cancer.

[24]  G. Peters,et al.  Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. , 2002, European journal of cancer.

[25]  E. Warner,et al.  Patient preferences for oral versus intravenous palliative chemotherapy. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  E. Lemarié,et al.  Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .